Phenotypic difference of normal plasma cells from mature myeloma cells.
Phenotypic difference of normal plasma cells from mature myeloma cells.
复制标题
DOI：
10.1182/blood.v81.10.2658.bloodjournal81102658
复制
发表时间：
1993-05
期刊：
影响因子：
20.3
通讯作者：
H. Harada;M. Kawano;N. Huang;Y. Harada;K. Iwato;O. Tanabe;Hideo Tanaka;A. Sakai;H. Asaoku
中科院分区：
文献类型：
--
作者：
H. Harada;M. Kawano;N. Huang;Y. Harada;K. Iwato;O. Tanabe;Hideo Tanaka;A. Sakai;H. Asaoku
我们最近表明，异硫氰酸荧光素 (FITC)-抗 CD38 抗体的双色分析可以清楚地区分骨髓瘤细胞（浆细胞）与骨髓中的其他造血细胞。单独的骨髓瘤细胞（浆细胞）位于CD38强阳性（++）部分。为了进一步在表型上区分正常浆细胞和成熟骨髓瘤细胞，我们通过使用 FITC-抗 CD38 抗体的双色流式细胞术和使用 VLA-4、MPC-1、CD44、CD56、CD19、CD20、CD24 或 CD10 抗体进行藻红蛋白染色来检查正常浆细胞和骨髓瘤细胞的免疫表型。 7名健康捐献者的骨髓、4名慢性扁桃体炎患者的扁桃体、1名特发性血小板减少性紫癜患者的脾脏和2名慢性淋巴结炎患者的淋巴结中，正常浆细胞分别为VLA-4+VLA-5+MPC-1+CD44+CD19+CD56-。另一方面，成熟的骨髓瘤细胞（20例中有12例）VLA-4+VLA-5+MPC-1+均为CD19-，其中大部分为CD56+，在我们检测的20例骨髓瘤中没有CD19+CD56-表型的骨髓瘤细胞。因此，就CD19和CD56的表达而言，来自各种组织的正常浆细胞都是CD19+CD56-，而骨髓瘤细胞不具有CD19+CD56-表型。根据这一发现，我们研究了意义未明的单克隆丙种球蛋白病 (MGUS) 中浆细胞 (CD38++ 部分) 上 CD19 和 CD56 的表达。在我们测试的所有 5 例 MGUS 病例中均发现了 CD19+CD56- 和 CD19-DC56+ 浆细胞，表明 MGUS 由表型正常的浆细胞和骨髓瘤细胞组成。因此，推测用抗CD19和抗CD56抗体对浆细胞进行表型分析可以区分正常浆细胞和恶性浆细胞（骨髓瘤细胞），并且即使在MGUS或骨髓瘤前状态也可以检测恶性浆细胞。
We have recently shown that two-color analysis with fluorescein isothiocyanate (FITC)-anti-CD38 antibody could clearly distinguish myeloma cells (plasma cells) from other hematopoietic cells in the bone marrow. Myeloma cells (plasma cells) alone were located at CD38strong positive (++) fractions. To further distinguish normal plasma cells from mature myeloma cells phenotypically, we examined immunophenotypes of normal plasma cells and myeloma cells by two-color flow cytometry with FITC-anti-CD38 antibody and phycoerythrin staining with antibody to VLA-4, MPC-1, CD44, CD56, CD19, CD20, CD24, or CD10. Normal plasma cells were all VLA-4+VLA-5+MPC-1+CD44+ CD19+CD56- in the bone marrows from seven healthy donors, tonsils from four patients with chronic tonsillitis, a spleen from one patient with idiopathic thrombocytopenic purpura, and lymph nodes from two patients with chronic lymphadenitis, respectively. On the other hand, mature myeloma cells (12 of 20 cases), VLA-4+VLA-5+MPC-1+, were all CD19- and most of them CD56+, and there were no myeloma cells with the CD19+CD56- phenotype in the 20 cases of myelomas we tested. Thus, as for the expression of CD19 and CD56, normal plasma cells from various tissues are all CD19+CD56-, whereas no myeloma cells have the CD19+CD56- phenotype. According to this finding, we investigated the expression of CD19 and CD56 on plasma cells (CD38++ fractions) in monoclonal gammopathy of undetermined significance (MGUS). Both CD19+CD56- and CD19-DC56+ plasma cells were found in all five cases of MGUS we tested, suggesting that MGUS consists of phenotypically normal plasma cells and myeloma cells. Therefore, it is reasoned that phenotypic analysis of plasma cells with anti-CD19 and anti-CD56 antibodies can distinguish normal plasma cells from malignant plasma cells (myeloma cells), and can detect malignant plasma cells even in MGUS or premyeloma states.